• Home A global leader in neuro-scientific radiosurgery.

A global leader in neuro-scientific radiosurgery.

Phase two will contain the development of the prototype that’s intended to be used as a critical component of cargo scanning systems by the Division of Homeland Protection. ‘We are proud to end up being identified by the U.S. Authorities for our commitment to creativity. While we concentrate on further advancing our core item providing, the CyberKnife Robotic Radiosurgery System, we’re pleased to be able to conduct innovative research and advancement stimulated by the federal government in anticipation of their future technology needs,’ stated Chris A. Raanes, senior vice president and chief operating officer for Accuray. ‘As a leader in advanced linear accelerator technology, it’s great to observe how our tested technology, used to take care of cancer, may also be applicable and equally as effective for various other important applications.’ Accuray’s technology is fantastic for mobile applications due to the lightweight and small design, which sets the company’s technology apart from others.

New therapies specifically developed for migraine avoidance are urgently needed specifically for the considerable proportion of migraine victims who have frequent attacks and also have significant disability within their daily lives. Targeting mGluR5 signaling with ADX10059 can be an interesting approach that is showing significant guarantee in early scientific evaluation. The medical trial data for ADX10059, presented here at AAN, proved the concept that by terminating severe attacks in a few patients, mGluR5 inhibition is important in migraine pathophysiology. Today we are looking forward to the info from our ongoing Stage IIb migraine prevention research in the first fifty % of 2013, stated Charlotte Keywood, chief medical officer.New therapies specifically developed for migraine avoidance are urgently needed specifically for the considerable proportion of migraine victims who have frequent attacks and also have significant disability within their daily lives. Targeting mGluR5 signaling with ADX10059 can be an interesting approach that is showing significant guarantee in early scientific evaluation. The medical trial data for ADX10059, presented here at AAN, proved the concept that by terminating severe attacks in a few patients, mGluR5 inhibition is important in migraine pathophysiology. Today we are looking forward to the info from our ongoing Stage IIb migraine prevention research in the first fifty % of 2013, stated Charlotte Keywood, chief medical officer.